{
    "response": "**Overall Treatment Decision:** Yes\n\n**Specific Treatment Recommendations:**\n\n*   **Treatment:** Intravenous Methylprednisolone\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** First-line treatment for acute optic neuritis and myelitis to accelerate recovery Patient is afebrile with normal inflammatory markers, making active bacterial sepsis unlikely\n\n*   **Treatment:** Gastroprotection (e.g., Omeprazole)\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** To prevent peptic ulceration associated with high-dose corticosteroid therapy\n\n*   **Treatment:** Disease Modifying Therapy (e.g., Ocrelizumab/Infliximab)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Specific diagnosis (MS vs. Sarcoidosis vs. NMO) must be confirmed via MRI and serology first Long-term risks require definitive diagnostic criteria to be met\n\n\ntreatments = [{\"treatment\": \"Intravenous Methylprednisolone\", \"timing\": \"Start Now\", \"reasons\": [\"First-line treatment for acute optic neuritis and myelitis to accelerate recovery\", \"Patient is afebrile with normal inflammatory markers, making active bacterial sepsis unlikely\"]}, {\"treatment\": \"Gastroprotection (e.g., Omeprazole)\", \"timing\": \"Start Now\", \"reasons\": [\"To prevent peptic ulceration associated with high-dose corticosteroid therapy\"]}, {\"treatment\": \"Disease Modifying Therapy (e.g., Ocrelizumab/Infliximab)\", \"timing\": \"Delay\", \"reasons\": [\"Specific diagnosis (MS vs. Sarcoidosis vs. NMO) must be confirmed via MRI and serology first\", \"Long-term risks require definitive diagnostic criteria to be met\"]}]"
}